Literature DB >> 1397699

Lp(a) concentrations in NIDDM.

S M Haffner1, P A Morales, M P Stern, M K Gruber.   

Abstract

NIDDM patients have a two- to fourfold increased risk of CHD relative to nondiabetic subjects. This excess risk is explained only partially by increased levels of standard risk factors. We compared the plasma concentrations of Lp(a) in NIDDM patients (n = 260) and nondiabetic subjects (n = 336) who participated in a population-based study (San Antonio Heart Study). Lp(a) was measured using a monoclonal anti-Lp(a) antibody. NIDDM patients and nondiabetic subjects had similar Lp(a) concentrations for both men (13.6 +/- 1.5 vs. 16.1 +/- 1.4 mg/dl) and women (12.6 +/- 0.8 vs. 15.9 +/- 1.3 mg/dl) (P = 0.361). Duration of diabetes and level of fasting glycemia were not significantly related to Lp(a) concentrations. Lp(a) levels were significantly higher in patients who had higher total and LDL cholesterol levels. We conclude that in a large population-based study, Lp(a) levels are not increased in NIDDM patients.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1397699     DOI: 10.2337/diab.41.10.1267

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  21 in total

1.  Serum lipoprotein (a) concentrations are inversely associated with T2D, prediabetes, and insulin resistance in a middle-aged and elderly Chinese population.

Authors:  Lin Ding; An Song; Meng Dai; Min Xu; Wanwan Sun; Baihui Xu; Jichao Sun; Tiange Wang; Yu Xu; Jieli Lu; Weiqing Wang; Yufang Bi; Guang Ning
Journal:  J Lipid Res       Date:  2015-02-03       Impact factor: 5.922

2.  LPA kringle IV type 2 is associated with type 2 diabetes in a Chinese population with very high cardiovascular risk.

Authors:  Di-Li-Da-Er Mu-Han-Ha-Li 迪丽达尔 木汗哈力; Tian-Yu Zhai 翟天羽; Yan Ling 凌雁; Xin Gao 高鑫
Journal:  J Lipid Res       Date:  2018-03-06       Impact factor: 5.922

3.  In search of a physiological function of lipoprotein(a): causality of elevated Lp(a) levels and reduced incidence of type 2 diabetes.

Authors:  Sotirios Tsimikas
Journal:  J Lipid Res       Date:  2018-04-02       Impact factor: 5.922

4.  Plasma lipoprotein (a) concentration in diabetes mellitus.

Authors:  J Vendrell; C Gutiérrez; R Pastor; C Richart
Journal:  Diabetologia       Date:  1993-09       Impact factor: 10.122

Review 5.  New concepts in diabetes mellitus. II: Complications.

Authors:  M Vanderpump; R Taylor
Journal:  Postgrad Med J       Date:  1994-07       Impact factor: 2.401

Review 6.  Dyslipidemia of the metabolic syndrome.

Authors:  Giacomo Ruotolo; Barbara V Howard
Journal:  Curr Cardiol Rep       Date:  2002-11       Impact factor: 2.931

7.  Lipoprotein (a) in type 2 diabetes mellitus: Relation to LDL:HDL ratio and glycemic control.

Authors:  Seema Singla; Kiranjeet Kaur; Gurdeep Kaur; Habir Kaur; Jasbinder Kaur; Shivani Jaswal
Journal:  Int J Diabetes Dev Ctries       Date:  2009-04

Review 8.  Prevention of complications in non-insulin-dependent diabetes mellitus (NIDDM).

Authors:  B H Wolffenbuttel; T W van Haeften
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

9.  Apolipoprotein(a) and cardiovascular disease in type 2 (non-insulin-dependent) diabetic patients with and without diabetic nephropathy.

Authors:  F S Nielsen; A I Voldsgaard; M A Gall; P Rossing; E Hommel; P Andersen; J Dyerberg; H H Parving
Journal:  Diabetologia       Date:  1993-05       Impact factor: 10.122

10.  Association of elevated lipoprotein(a) levels and coronary heart disease in NIDDM patients. Relationship with apolipoprotein(a) phenotypes.

Authors:  J Ruiz; J Thillet; T Huby; R W James; D Erlich; P Flandre; P Froguel; J Chapman; P Passa
Journal:  Diabetologia       Date:  1994-06       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.